La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Panion & Bf Biotech Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Panion & Bf Biotech ha un patrimonio netto totale di NT$1.9B e un debito totale di NT$725.6M, che porta il suo rapporto debito/patrimonio netto a 39.1%. Le sue attività totali e le sue passività totali sono rispettivamente NT$3.3B e NT$1.4B. L'EBIT di Panion & Bf Biotech è NT$193.4M rendendo il suo rapporto di copertura degli interessi 153.1. Ha liquidità e investimenti a breve termine pari a NT$581.9M.

Informazioni chiave

39.1%

Rapporto debito/patrimonio netto

NT$725.56m

Debito

Indice di copertura degli interessi	207x
Contanti	NT$581.86m
Patrimonio netto	NT$1.85b
Totale passività	NT$1.40b
Totale attività	NT$3.25b

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Is Panion & Bf Biotech (TWSE:1760) A Risky Investment?

Aug 13

Here's Why Panion & Bf Biotech (TPE:1760) Has A Meaningful Debt Burden

Apr 07

Is Panion & Bf Biotech Inc. (TPE:1760) A Strong Dividend Stock?

Mar 03

Introducing Panion & Bf Biotech (TPE:1760), A Stock That Climbed 47% In The Last Three Years

Feb 04

Are Panion & Bf Biotech Inc.'s (TPE:1760) Mixed Financials Driving The Negative Sentiment?

Jan 09

Panion & Bf Biotech (TPE:1760) Has A Somewhat Strained Balance Sheet

Dec 14

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( NT$1.5B ) di 1760 superano le sue passività a breve termine ( NT$1.1B ).

Passività a lungo termine: Le attività a breve termine di 1760 ( NT$1.5B ) superano le sue passività a lungo termine ( NT$272.0M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Il rapporto debito netto/patrimonio netto ( 7.8% ) di 1760 è considerato soddisfacente.

Riduzione del debito: Il rapporto debito/patrimonio netto di 1760 è aumentato da 0% a 39.1% negli ultimi 5 anni.

Copertura del debito: Il debito di 1760 è ben coperto dal flusso di cassa operativo ( 40.7% ).

Copertura degli interessi: I pagamenti degli interessi sul debito di 1760 sono ben coperti dall'EBIT ( 153.1 x copertura).

Panion & Bf Biotech Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Is Panion & Bf Biotech (TWSE:1760) A Risky Investment?

Here's Why Panion & Bf Biotech (TPE:1760) Has A Meaningful Debt Burden

Panion & Bf Biotech (TPE:1760) Has A Somewhat Strained Balance Sheet

Recent updates

Second quarter 2024 earnings released: EPS: NT$0.23 (vs NT$0.20 in 2Q 2023)

Is Panion & Bf Biotech (TWSE:1760) A Risky Investment?

Panion & Bf Biotech Inc. to Report Q2, 2024 Results on Aug 13, 2024

Upcoming dividend of NT$1.50 per share

Panion & Bf Biotech Inc. Announces the Cash Dividend, Payable on July 10, 2024

Panion & Bf Biotech Inc. to Report Q1, 2024 Results on May 10, 2024

Full year 2023 earnings released: EPS: NT$0.90 (vs NT$2.13 in FY 2022)

Panion & Bf Biotech Inc., Annual General Meeting, May 24, 2024

New minor risk - Share price stability

Panion and BF Biotech Inc. Obtains Nephoxil NDA Approval

Panion & Bf Biotech Inc. Announces Nephoxil Receives NMPA Acceptance for NDA Application Submission

New minor risk - Earnings quality

Second quarter 2023 earnings released: EPS: NT$0.20 (vs NT$1.88 in 2Q 2022)

Upcoming dividend of NT$2.00 per share at 1.5% yield

Panion & Bf Biotech Inc. Announces the Cash Dividend, payable on August 11, 2023

Investor sentiment deteriorates as stock falls 15%

Full year 2022 earnings released: EPS: NT$2.13 (vs NT$1.32 in FY 2021)

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: NT$0.91 (vs NT$0.77 in 3Q 2021)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: NT$1.88 (vs NT$0.97 in 2Q 2021)

Upcoming dividend of NT$1.50 per share

Investor sentiment deteriorated over the past week

First quarter 2022 earnings released: EPS: NT$0.46 (vs NT$0.32 loss in 1Q 2021)

Price target increased to NT$106

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS NT$0.77 (vs NT$0.038 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS NT$0.97 (vs NT$0.099 loss in 2Q 2020)

Upcoming dividend of NT$0.70 per share

Price target increased to NT$108

First quarter 2021 earnings released: NT$0.32 loss per share (vs NT$0.009 profit in 1Q 2020)

Here's Why Panion & Bf Biotech (TPE:1760) Has A Meaningful Debt Burden

Full year 2020 earnings released: EPS NT$0.36 (vs NT$2.10 in FY 2019)

Panion & Bf Biotech Inc., Annual General Meeting, Jun 04, 2021

Is Panion & Bf Biotech Inc. (TPE:1760) A Strong Dividend Stock?

Introducing Panion & Bf Biotech (TPE:1760), A Stock That Climbed 47% In The Last Three Years

New 90-day low: NT$74.10

Price target lowered to NT$97.00

Are Panion & Bf Biotech Inc.'s (TPE:1760) Mixed Financials Driving The Negative Sentiment?

New 90-day low: NT$80.60

Panion & Bf Biotech (TPE:1760) Has A Somewhat Strained Balance Sheet

New 90-day low: NT$91.10

Third quarter 2020 earnings released: NT$0.04 loss per share

Revenue misses expectations

New 90-day low: NT$104

New 90-day low: NT$112

Price target raised to NT$141

First half earnings released

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane